跳至主要内容
临床试验/NL-OMON26278
NL-OMON26278尚未招募不适用

Effect of oral Curcumin on Gut Microbiota Composition in patients with Diabetes Type II, Ulcerative Colitis, Crohn's disease and healthy subjects

none0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Aged 18-65 years
  • - Stable therapy (i.e. no major dosage changes in the last three months)
  • - Able to give written informed consent

排除标准

  • - Tobacco use (as there are indications this influences the gut microbiota, Huang et al. 2019)
  • - Alcohol use > 1 units/day,
  • - Excessive weight loss of >10% in the last 3 months,
  • - Levels of plasma aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) 2.5 times or more the upper limit of the normal range,
  • - Other liver abnormalities,
  • - Known intolerance to curcumin or curcumin-derivatives,
  • - Use of food supplements containing curcumin or/and black pepper for at least 3 days prior to each study day and two weeks prior to the study,
  • - Daily use of non-steroidal anti-inflammatory drugs (NSAIDS),
  • - Use of proton pump inhibitors (as this influences intestinal microbiota composition)
  • - Eating/drinking of grapefruit and grapefruit-containing products or star fruit during the course of the study,
  • - Incomplete information or unwillingness to comply with the intervention,
  • - Participation in other intervention studies 3 months before or after the duration of this study.

研究者

发起方
none

相似试验